Back to discover
Disease
Chemotherapy-Related Cognitive Impairment
Late-stage therapeutic developmentEmerging research
1
Publications
3
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2024-03-06Science translational medicine
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
No activity recorded in this window. Try a wider timeframe.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes2
- Chemotherapy-Related Cognitive Impairment1
- Cognitive Dysfunction1
Leading journals1
- Science translational medicine1
Leading researchers8
- Abdurrob F1
- Blanco-Duque C1
- Islam MR1
- James BT1
- Kahn MC1
- Kellis M1
- Kim T1
- Lavoie NS1
Affiliations (unnormalised)4
- Broad Institute of MIT and Harvard1
- Computer Science and Artificial intelligence Laboratory1
- Massachusetts Institute of Technology1
- Picower Institute for Learning and Memory1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
The diminished or impaired mental and/or intellectual function associated with the chemical treatment of cancer.
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.